Ten years' disease-free survival of advanced epithelial ovarian cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy A case report and literature review

被引:2
|
作者
Zhang, Jue [1 ]
Mei, Liejun [2 ]
Wang, Fubing [3 ]
Li, Yan [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Radiol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Clin Lab, Wuhan 430071, Peoples R China
基金
北京市自然科学基金;
关键词
advanced ovarian cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; HIPEC; PACLITAXEL; CISPLATIN;
D O I
10.1097/MD.0000000000023404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: One of the most distinctive features of epithelial ovarian cancer is tendency to disseminate into peritoneal cavity to form peritoneal carcinomatosis, indicating advanced disease with poor prognosis. Patient concerns: A fifty-year-old patient had a chief complaint of an abdominal distension lasting 1 month. Diagnoses: The patient was diagnosed with advanced epithelial ovarian cancer with peritoneal carcinomatosis by computed tomography scan, tumor markers, endoscopy examination, and pathology. Interventions: The patient was treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy followed by 8 cycles of systemic chemotherapy. Outcomes: Till March 9, 2020, the patient has disease-free survival over 10 years. Lessons: The application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy combined with systematic chemotherapy may improve survival dramatically for the patients with epithelial ovarian cancer and peritoneal carcinomatosis and should be considered as an option of a relatively new regime.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Perianesthesia Measurement During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Procedure: A Case Report and Review of the Literature
    Li, Dan
    Henker, Richard
    Zhang, Fei
    JOURNAL OF PERIANESTHESIA NURSING, 2019, 34 (01) : 198 - 205
  • [22] Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer
    Ayhan, Ali
    Akilli, Huseyin
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2021, 152 (02) : 202 - 207
  • [23] Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
    Lei, Ziying
    Wang, Yue
    Wang, Jiahong
    Wang, Ke
    Tian, Jun
    Zhao, Ying
    Chen, Lipai
    Wang, Jin
    Luo, Jiali
    Jia, Manman
    Tang, Hongsheng
    He, Qingjun
    Liao, Quanxing
    Yang, Xiansheng
    Guan, Tianpei
    Wang, Li
    Cui, Shuzhong
    JAMA NETWORK OPEN, 2020, 3 (08) : E2013940
  • [24] A rare case of recurrent epidermoid anal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—case report
    Vera Pravong
    Alexandre Brind’Amour
    Lucas Sidéris
    Pierre Dubé
    Jean-François Tremblay
    World Journal of Surgical Oncology, 18
  • [25] Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Le Saux, Olivia
    Decullier, Evelyne
    Freyer, Gilles
    Glehen, Olivier
    Bakrin, Naoual
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2019, 35 (01) : 652 - 657
  • [26] Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer
    Kohut, Adrian
    Anderson, Matthew L.
    Andikyan, Vaagn
    Yasukawa, Maya
    Nguy, Lindsey
    Karachristos, Andreas
    Nywening, Timothy
    Mor, Gil
    Gogoi, Radhika
    Cohen, Joshua G.
    Lin, Jeff F.
    Rutherford, Thomas J.
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 4326 - 4334
  • [27] Exploring the Survival Determinants in Recurrent Ovarian Cancer: The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Geca, Katarzyna
    Litwinski, Jakub
    Ostrowski, Tomasz
    Swietlicka, Izabela
    Polkowski, Wojciech P.
    Skorzewska, Magdalena
    CANCERS, 2024, 16 (11)
  • [28] Electrolyte and hematological abnormalities in patients with advanced epithelial ovarian cancers treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or neoadjuvant chemotherapy plus CRS/HIPEC
    Diaz-Montes, T. P.
    Velez-Mejia, C.
    Sittig, M.
    MacDonald, R.
    Gushchin, V.
    Ducie, J. A.
    Ryu, H. S.
    Sardi, A.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 144 - 144
  • [29] Late Recurrence of Ovarian Cancer after 18 Years of Disease-Free Survival: A Case Report and Review of the Literature
    Suzuki, Yoko
    Eguchi, Satoko
    Arimoto, Takahide
    CASE REPORTS IN OBSTETRICS AND GYNECOLOGY, 2024, 2024
  • [30] Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database
    Sun, Jian-Hua
    Ji, Zhong-He
    Yu, Yang
    Wu, Hai-Tao
    Huang, Chao-Qun
    Zhang, Qian
    Yang, Xiao-Jun
    Yonemura, Yutaka
    Li, Yan
    TRANSLATIONAL ONCOLOGY, 2016, 9 (02): : 130 - 138